A journey into e-resource administration hell

The author discusses the administrative problems which can still occur when looking after a large and complex portfolio of electronic resources, and focuses on some of the recurring ‘nightmares’ involving e-journals in particular. Amongst the subjects discussed are lost archives, activation codes which change without anyone being told, unreasonable expiry dates, poor service, wandering URLs, lack of publicity, failure to keep licensing conditions, and title changes. The article ends with a look at some emerging examples of excellent practice to do with e-journal management, proving all parties involved can work together to ensure a smooth and efficient service

Cosmic distance inference from purely geometric BAO methods: Linear point standard ruler and correlation function model fitting

12 pages, 2 tablesInternational audienceLeveraging the Baryon Acoustic Oscillations (BAO) feature present in clustering 2-point statistics, we aim to measure cosmological distances independently of the underlying background cosmological model. However this inference is complicated by late-time non-linearities that introduce model and tracer dependencies in the clustering correlation function and power spectrum, which must be properly accounted for. With this in mind, we introduce the "Purely-Geometric-BAO," which provides a rigorous tool to measure cosmological distances without assuming a specific background cosmology. We focus on the 2-point clustering correlation function monopole, and show how to implement such an inference scheme employing two different methodologies: the Linear Point standard ruler (LP) and correlation-function model-fitting (CF-MF). For the first time we demonstrate how, by means of the CF-MF, we can measure very precisely the sound-horizon/isotropic-volume-distance ratio, $r_{d}/D_{V}(\bar{z})$, while correctly propagating all the uncertainties. Using synthetic data, we compare the outcomes of the two methodologies, and find that the LP provides up to $50\%$ more precise measurements than the CF-MF. Finally, we test a procedure widely employed in BAO analyses: fitting the 2-point function while fixing the cosmological and the non-linear-damping parameters at fiducial values. We find that this underestimates the distance errors by nearly a factor of $2$. We thus recommend that this practice be reconsidered, whether for parameter determination or model selection

A Description of Protocols for Private Credentials

This document provides a short description of practical protocols for private credential systems. We explain the basic concepts and mechanisms behind issuing and showing of private credentials and e-cash. The goal is to describe concisely how practical private credential systems can be achieved and not to provide intuition or motivation for the technology; for information on these subjects, see [1,2,3]. We give the details of one specific type of practical protocols for private credentials; other choices of functionalities and optimizations are possible. The reader is assumed to have general knowledge of basic concepts of cryptography such as the Discrete Logarithm problem, basic group theory and hash functions. For security proofs and more elaborate descriptions of the techniques used we refer the reader to [2]

Johns Hopkins Medicine responds to COVID-19: Adjusting patient- family- and staff-centered care

The extraordinary impact of the novel coronavirus disease 2019 (COVID-19) on the health care industry included a major, nearly immediate paradigm shift in the visitation policy for Johns Hopkins Medicine. This large health system, comprising six hospitals, a home care group, community physician practices and satellite outpatient sites moved from essentially open visitation to no visitation, creating an entirely new set of needs for our staff, patients and their loved ones. We developed new ways of communicating and connecting staff members, staff and patients, staff and the patient’s loved ones, and patients and their loved ones. Our intent was to maintain our commitment to patient- and family-centered care, to alleviate the anxiety and stress from this devastating pandemic to the extent possible. This article describes approaches taken by the health system’s Patient Experience leadership team and others to develop resources that educate patients, loved ones and staff about the process changes and facilitate incorporation of these new ways of communicating and connecting. The content is organized into three areas: including staff resources, consumer resources and resources that support consumer engagement. Many of the changes have been well received, enhancing our pre-COVID-19 ability to connect with one another and will be assimilated into our culture for the long term. We plan to develop objective measures of the effectiveness for approaches that outlive COVID-19 and enhance patient-centered care. Experience Framework This article is associated with the Patient, Family & Community Engagement lens of The Beryl Institute Experience Framework. (http://bit.ly/ExperienceFramework) Access other PXJ articles related to this lens. Access other resources related to this lens

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II):a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

Background Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomodulator use if topical medication is not sufficient to control the inflammation. We aimed to assess the efficacy and safety of adalimumab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids. Methods We did this multicentre, double-masked, randomised, placebo-controlled phase 3 trial at 62 study sites in 21 countries in the USA, Canada, Europe, Israel, Australia, and Latin America. Patients (aged >= 18 years) with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10-35 mg/day of prednisone were randomly assigned (1: 1), via an interactive voice and web response system with a block size of four, to receive either subcutaneous adalimumab (loading dose 80 mg; biweekly dose 40 mg) or placebo, with a mandatory prednisone taper from week 2. Randomisation was stratified by baseline immunosuppressant treatment. Sponsor personnel with direct oversight of the conduct and management of the study, investigators, study site personnel, and patients were masked to treatment allocation. The primary efficacy endpoint was time to treatment failure, a multicomponent endpoint encompassing new active inflammatory chorioretinal or inflammatory retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, and visual acuity. Analysis was done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01124838. Findings Between Aug 10, 2010, and May 14, 2015, we randomly assigned 229 patients to receive placebo (n=114) or adalimumab (n=115); 226 patients comprised the intention-to-treat population. Median follow-up time was 155 days (IQR 77-357) in the placebo group and 245 days (119-564) in the adalimumab group. Treatment failure occurred in 61 (55%) of 111 patients in the placebo group compared with 45 (39%) of 115 patients in the adalimumab group. Time to treatment failure was significantly improved in the adalimumab group compared with the placebo group (median not estimated [>18 months] vs 8.3 months; hazard ratio 0.57, 95% CI 0.39-0.84; p=0.004). The 40th percentile for time to treatment failure was 4.8 months in the placebo group and 10.2 months in the adalimumab group. No patients in either group had opportunistic infections (excluding oral candidiasis and tuberculosis). No malignancies were reported in the placebo group whereas one (1%) patient in the adalimumab group reported non-serious squamous cell carcinoma. The most common adverse events were arthralgia (12 [11%] patients in the placebo group and 27 [23%] patients in the adalimumab group), nasopharyngitis (16 [17%] and eight [16%] patients, respectively), and headache (17 [15%] patients in each group). Interpretation Adalimumab significantly lowered the risk of uveitic flare or loss of visual acuity upon corticosteroid withdrawal in patients with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by systemic corticosteroids. No new safety signals were observed and the rate of adverse events was similar between groups. These findings suggest that adalimumab is well tolerated and could be an effective treatment option in this patient population. An open-label extension study (NCT01148225) is ongoing to provide long-term safety data for adalimumab in patients with non-infectious uveitis

N-Cadherin Expression Level Distinguishes Reserved versus Primed States of Hematopoietic Stem Cells

SummaryOsteoblasts expressing the homophilic adhesion molecule N-cadherin form a hematopoietic stem cell (HSC) niche. Therefore, we examined how N-cadherin expression in HSCs relates to their function. We found that bone marrow (BM) cells highly expressing N-cadherin (N-cadherinhi) are not stem cells, being largely devoid of a Lineage−Sca1+cKit+ population and unable to reconstitute hematopoietic lineages in irradiated recipient mice. Instead, long-term HSCs form distinct populations expressing N-cadherin at intermediate (N-cadherinint) or low (N-cadherinlo) levels. The minority N-cadherinlo population can robustly reconstitute the hematopoietic system, express genes that may prime them to mobilize, and predominate among HSCs mobilized from BM to spleen. The larger N-cadherinint population performs poorly in reconstitution assays when freshly isolated but improves in response to overnight in vitro culture. Their expression profile and lower cell-cycle entry rate suggest N-cadherinint cells are being held in reserve. Thus, differential N-cadherin expression reflects functional distinctions between two HSC subpopulations